隐丹参酮衍生物的设计、合成及心肌保护作用

doi:10.6023/cjoc202110004

有机化学 ›› 2022, Vol. 42 ›› Issue (6): 1735-1746.DOI: 10.6023/cjoc202110004 上一篇下一篇

研究论文

隐丹参酮衍生物的设计、合成及心肌保护作用

孟方凤^a, 周佳慧^a, 程鑫涛^a, 许佳慧^a, 康磊^a, 李蝶^a, 王东浩^a, 毕跃峰^a^,^b^,^*()

a 郑州大学药学院郑州 450001
b 药物关键制备技术教育部重点实验室郑州 450001

收稿日期:2021-10-03 修回日期:2021-12-27 发布日期:2022-03-03
通讯作者: 毕跃峰
作者简介:
† 共同第一作者
基金资助:
河南省自然科学基金(182300410348)

Design, Synthesis and Cardioprotection of Cryptotanshinone Derivatives

Fangfeng Meng^a, Jiahui Zhou^a, Xintao Cheng^a, Jiahui Xu^a, Lei Kang^a, Die Li^a, Donghao Wang^a, Yuefeng Bi^a^,^b()

a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
b Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou 450001

Received:2021-10-03 Revised:2021-12-27 Published:2022-03-03
Contact: Yuefeng Bi
About author:
† These authors contributed equally to this work
Supported by:
Natural Science Foundation of Henan Province(182300410348)

文章分享

1. 221735S.pdf(5102KB)

摘要/Abstract

隐丹参酮(CT)是丹参中主要的脂溶性活性成分, 具有心肌保护及抗氧化等作用. 为了改善其极性, 提高活性, 增加作用靶点, 将其与丹参中水溶性活性成分丹参酚酸及其类似物进行1位杂化合成. 共合成了42个衍生物, 均为新化合物. 与CT相比, 衍生物的极性得到了改善. 利用体外缺氧/复氧损伤(HRI)模型实验, 初步评价了衍生物的心肌保护作用. 结果表明, 与CT相比, 大部分衍生物心肌细胞保护作用增强, 其中有6个化合物作用显著. 利用Sirtuin 1 (SIRT1)高通量活性筛选平台和分子对接技术, 初步探索了活性衍生物可能的作用机制. 构效关系研究表明, 衍生物1位R构型的产物活性优于S构型的产物, 具有供电子取代基的芳香酸衍生物的活性优于具有吸电子取代基的芳香酸衍生物.

关键词: 隐丹参酮, 芳香酸, 杂化, 心肌保护

Cryptotanshinone (CT) is the major lipid-soluble component of Salvia miltiorrhiza, which has myocardial protection and antioxidant effects. To improve its polarity, activity and targets, CT was hybridized with salvianolic acids, the water-soluble active component in salvia miltiorrhiza, and its analogues at its 1 site. A total of 42 derivatives were synthesized, all of which are new compounds. Compared with CT, the polarities of the derivatives were improved. The cardioprotective effects of derivatives were preliminarily evaluated by hypoxia/reoxygenation injury (HRI) model in vitro. The results showed that the activities of most derivatives were enhanced compared with CT, and 6 compounds showed significant effects. Sirtuin 1 (SIRT1) high-throughput activity screening platform and molecular docking technology were used to explore the possible mechanism preliminarily. Structure-activity relationship studies showed that the product activity of 1-position R configuration was better than that of S-configuration, and the activity of aromatic acid derivatives with electron-donating substituents was better than that of with electron-absorbing substituents.

Key words: cryptotanshinone, aromatic acid, hybridization, myocardial protection

引用此文

孟方凤, 周佳慧, 程鑫涛, 许佳慧, 康磊, 李蝶, 王东浩, 毕跃峰. 隐丹参酮衍生物的设计、合成及心肌保护作用[J]. 有机化学, 2022, 42(6): 1735-1746.

Fangfeng Meng, Jiahui Zhou, Xintao Cheng, Jiahui Xu, Lei Kang, Die Li, Donghao Wang, Yuefeng Bi. Design, Synthesis and Cardioprotection of Cryptotanshinone Derivatives[J]. Chinese Journal of Organic Chemistry, 2022, 42(6): 1735-1746.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 8

参考文献 27

[1]	Nitsa, A.; Toutouza, M.; Machairas, N.; Mariolis, A.; Philippou, A.; Koutsiliers, M. In Vivo 2018, 32, 977. doi: 10.21873/invivo.11338
[2]	Kahleova, H.; Levin, S.; Barnard, N. D. Prog. Cardiovasc. Dis. 2018, 61, 54. doi: S0033-0620(18)30087-2 pmid: 29800598
[3]	Li, Z.; Xu, S.; Liu, P. Acta Pharmacol. Sin. 2018, 39, 802.
[4]	Cheng, T. O. Int. J. Cardiol. 2007, 121, 9. doi: 10.1016/j.ijcard.2007.01.004
[5]	Ren, J.; Fu, L.; Nile, S. H.; Zhang, J.; Kai, G. Front. Cardiovasc Smooth Muscle Pharmacol. 2019, 10, 53.
[6]	Wang, X.; Morris-Natschke, S. L.; Lee, K. H. Med. Res. Rev. 2007, 27, 133. doi: 10.1002/med.20077
[7]	Su, C.-Y.; Ming, Q.-L.; Rahman, K.; Han, T.; Qin, L.-P. Chin. J. Nat. Med. 2015, 13, 163.
[8]	Wu, Y.-B.; Ni, Z.-Y.; Shi, Q.-W.; Domg, M.; Kiyota, H.; Gu, Y.-G.; Cong, B. Chem. Rev. 2012, 112, 5967.
[9]	Kim, W. S.; Kim, D. O.; Yoon, S. J.; Kim, M. J.; Yoon, S. R.; Park, Y.-J.; Jung, H.; Kim, T.-D.; Kown, B.-M.; Choi, I. Biochem. Biophys. Res. Commun. 2012, 425, 340. doi: 10.1016/j.bbrc.2012.07.093
[10]	Lu, L.; Zhang, S.; Li, C.; Zhou, C.; Li, D.; Liu, P.; Huang, M.; Shen, X. Cell Death Dis. 2017, 8, e2767. doi: 10.1038/cddis.2017.174
[11]	Kwon, H.; Cho, E.; Jeon, J.; Kim, K. S.; Jin, Y. L.; Lee, Y. C.; Yun, J.; Park, S. J.; Yi, J. H.; Kim, D. H. Food Chem. Toxicol. 2020, 136, 111011. doi: 10.1016/j.fct.2019.111011
[12]	Zhou, L.; Zhong, Z.; Chow, M.-S. J. Clin. Pharmacol. 2005, 45, 1345.
[13]	Li, H.; Song, F.; Duan, L.-R.; Sheng, J.-J.; Xie, Y.-H.; Yang, Q.; Chen, Y.; Dong, Q.-Q.; Zhang, B.-L.; Wang, S.-W. Sci. Rep. 2016, 6, 23693. doi: 10.1038/srep23693
[14]	Xie, J.; Gao, S.; Li, L.; Xu, Y.-L.; Gao, S.-M.; Yu, C.-Q. Chin. Herb. Med. 2019, 50, 2257.
[15]	Li, S.; Zhang, B.; Zhang, N. BMC Syst. Biol. 2011, 5, 10. doi: 10.1186/1752-0509-5-10
[16]	Xu, J.-H. M.S. Dissertation, Zhengzhou University, Zhengzhou, 2019. (in Chinese)
	( 许佳慧, 硕士论文, 郑州大学, 郑州, 2019.)
[17]	Dai, Y.; Wang, Z.; Quan, M.; Lv, Y.; Li, Y.; Xin, H. B.; Qian, Y. Drug Des., evel. Ther. 2018, 12, 3573.
[18]	Shah, V. K.; Shalia, K. K. Indian Heart J. 2018, 70, 433. doi: S0019-4832(17)30051-2 pmid: 29961464
[19]	Han, D.; Sinclair, D. A.; Ellis, J. L.; Steegborn, C. Pharmacol. Ther. 2018, 188, 140. doi: 10.1016/j.pharmthera.2018.03.004
[20]	Bindu, S.; Pillai, V. B.; Gupta, M. P. Trends Endocrinol. Metab. 2016, 27, 563. doi: 10.1016/j.tem.2016.04.015
[21]	Eid, R. A.; Bin-Meferij, M. M.; El-kott, A. F.; Eleawa, S. M.; Zaki, M. S. A.; AI-Shraim, M.; EI-Sayed, F.; Eldeen, M. A.; Alkhateeb, M. A.; Alharbi, S. A.; Aldera, H.; Khalil, M. A. J. Cardiovasc. Trans. Res. 2020, 14, 619. doi: 10.1007/s12265-020-09984-5
[22]	Fan, J.; Fu, A.; Zhang, L. Quant. Biol. 2019, 7, 83. doi: 10.1007/s40484-019-0172-y
[23]	Zhang, W.; Yu, W.; Cai, G.; Zhu, J.; Zhang, C.; Li, S.; Guo, J.; Yin, J.; Chen, C.; Kong, L. Cell Death Dis. 2018, 9, 1098. doi: 10.1038/s41419-018-1139-z
[24]	Bi, Y.-F.; Wang, Z.-J.; Guan, R.-F.; Ye, Y.-T.; Chen, Y.-Y.; Zhang, Y.-B.; Liu, H.-M. Bioorg. Med. Chem. Lett. 2012, 22, 5141.
[25]	Bi, Y.-F.; Xu, H.-W.; Liu, X.-Q.; Zhang, X.-J.; Wang, Z.-J.; Liu, H.-M. Bioorg. Med. Chem. Lett. 2010, 20, 4892. doi: 10.1016/j.bmcl.2010.06.076
[26]	Han, D.; Sinclair, D. A.; Ellis, J. L.; Steegborn, C. Pharmacol. Ther. 2018, 188, 140. doi: 10.1016/j.pharmthera.2018.03.004
[27]	Ding, C.; Li, J.; Jiao, M.; Zhang, A. J. Nat. Prod. 2016, 79, 2514. doi: 10.1021/acs.jnatprod.6b00370

Compound	Log P	Compound	Log P
CT	1.22	8R	1.12
1S	1.11	13S	0.91
1R	0.97	13R	0.49
2R	0.69	17S	0.85
3S	0.61	17R	1.03
3R	0.95	21S	1.11
4R	1.15	21R	0.74
6S	0.47	23S	0.66
6R	0.99	23R	0.78
8S	0.82

Compound	Log P	Compound	Log P
CT	1.22	8R	1.12
1S	1.11	13S	0.91
1R	0.97	13R	0.49
2R	0.69	17S	0.85
3S	0.61	17R	1.03
3R	0.95	21S	1.11
4R	1.15	21R	0.74
6S	0.47	23S	0.66
6R	0.99	23R	0.78
8S	0.82

Product	Yield^a/%	Product	Yield^a/%
1S, 1R	45.2	13S, 13R	79.9
2S, 2R	60.9	14S, 14R	53.2
3S, 3R	81.2	15S, 15R	63.0
4S, 4R	66.5	16S, 16R	46.0
5	68.3	17S, 17R	50.3
6S, 6R	41.1	18S, 18R	39.0
7S, 7R	54.0	19S, 19R	49.9
8S, 8R	52.0	20S, 20R	51.8
9S, 9R	42.7	21S, 21R	47.8
10S, 10R	47.0	22	22.5
11	48.3	23S, 23R	15.5
12	33.6

Product	Yield^a/%	Product	Yield^a/%
1S, 1R	45.2	13S, 13R	79.9
2S, 2R	60.9	14S, 14R	53.2
3S, 3R	81.2	15S, 15R	63.0
4S, 4R	66.5	16S, 16R	46.0
5	68.3	17S, 17R	50.3
6S, 6R	41.1	18S, 18R	39.0
7S, 7R	54.0	19S, 19R	49.9
8S, 8R	52.0	20S, 20R	51.8
9S, 9R	42.7	21S, 21R	47.8
10S, 10R	47.0	22	22.5
11	48.3	23S, 23R	15.5
12	33.6

Compd.	Relative cardiomyo- cyte viability	Compd.	Relative cardiomyo- cyte viability
Normal group	1.000±0.009	10R	0.748±0.040
Model group	0.641±0.034	13S	0.811±0.015##
CT	0.778±0.035#	13R	0.785±0.044#
1S	0.885±0.036#	14S	0.675±0.043
1R	0.879±0.014##	14R	0.690±0.022
2S	0.929±0.053#	15S	0.666±0.030
2R	0.947±0.060##	15R	0.664±0.036
3S	0.952±0.054##	16	0.774±0.028#
3R	0.874±0.043##	17S	0.750±0.022#
4S	0.894±0.072#	17R	0.830±0.039#
4R	0.943±0.061##	18S	0.798±0.040#
5	0.880±0.063#	18R	0.729±0.034
6S	0.791±0.044#	19S	0.632±0.047
6R	0.913±0.121#	19R	0.634±0.016
7S	0.871±0.057#	20S	0.607±0.106
7R	0.881±0.066#	20R	0.622±0.023
8S	0.838±0.064#	21S	0.663±0.029
8R	0.646±0.045	21R	0.721±0.051
9S	0.692±0.046	23S	0.735±0.032#
9R	0.610±0.035	23R	0.637±0.025
10S	0.657±0.030

隐丹参酮衍生物的设计、合成及心肌保护作用

Design, Synthesis and Cardioprotection of Cryptotanshinone Derivatives

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 8

参考文献 27

相关文章 12

编辑推荐

相关统计

本文评价

[1]	鲍志成, 李慕尧, 王剑波. 铜催化芳基重氮乙酸酯与双[(频哪醇)硼基]甲烷的偶联反应[J]. 有机化学, 2023, 43(5): 1808-1814.
[2]	王明亮, 尹刘燕, 温甜甜, 张晓, 高杰, 王兰芝. 多官能团化的1,5-苯并二氮杂䓬类化合物的绿色合成[J]. 有机化学, 2022, 42(1): 160-171.
[3]	张坤, 谢向前, 史海霞, 沈月毛, 王浩鑫. 疣孢菌NS0172产生的邻二烷基取代芳香酸[J]. 有机化学, 2020, 40(4): 1038-1042.
[4]	张薇, 邓维. β-环糊精修饰的金纳米粒子:催化应用及分子选择性[J]. 有机化学, 2018, 38(11): 3002-3008.
[5]	吴义维, 范海波, 杨荣杰. 环梯形聚苯基硅倍半氧烷的硝化研究[J]. 有机化学, 2017, 37(7): 1870-1876.
[6]	宰文静, 蒋盼盼, 张新迎, Philippe M. Loiseau, 郭胜海, 范学森. 嘧啶核苷-查尔酮杂化体的合成及其抗利什曼原虫活性研究[J]. 有机化学, 2015, 35(6): 1335-1341.
[7]	沈舒苏. 乙烯基碳上的亲核取代反应[J]. 有机化学, 2014, 34(12): 2448-2455.
[8]	钟国琛, 彭家志, 李家明, 徐云根, 周鹏, 盛日正. 益母草碱类似物设计、合成及其Na^＋/H^＋交换器-1抑制活性[J]. 有机化学, 2011, 31(9): 1445-1451.
[9]	张天慧, 朴玲钰, 赵谡玲, 徐征, 杨磊, 刘祥志, 鞠思婷. 有机太阳能电池材料研究新进展[J]. 有机化学, 2011, 31(02): 260-272.
[10]	郑敏燕^*,a; 魏永生^a; 安忠维^b. 选择氧化法合成烷基多环苯酰氧基苯甲酸的研究[J]. 有机化学, 2008, 28(11): 1948-1953.
[11]	卜宪章,黄志纾,张敏,马林,肖桂武,钟增培,古练权. 丹参酮与胺类化合物的反应研究[J]. 有机化学, 2001, 21(3): 223-230.
[12]	荣国斌. 窗格烃的合成[J]. 有机化学, 1990, 10(1): 15-25.